Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Inmed Pharmaceuticals Inc
(NQ:
INM
)
0.3549
+0.0101 (+2.93%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Inmed Pharmaceuticals Inc
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
InMed Pharmaceuticals' Study Marks First Phase 2 Trial to Evaluate Cannabinol for Disease Treatment
December 10, 2021
InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following...
Via
Benzinga
InMed Pharmaceuticals’ (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol for Disease Treatment
December 10, 2021
Via
Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol as Therapeutic Option for Disease Treatment
December 09, 2021
Via
Investor Brand Network
InMed Pharmaceuticals Targeting Potential Therapeutics Addressing Unmet Needs
December 01, 2021
InMed Pharmaceuticals (NASDAQ: INM) recently filed a Patent Cooperation Treaty (“PCT”) application, which specifies a rare cannabinoid (new to InMed’s portfolio...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Strategy Toward Potential Therapeutics for Diseases with High Unmet Needs
November 30, 2021
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Strategy Toward Potential Therapeutics for Diseases with High Unmet Needs
November 30, 2021
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
InMed Pharmaceuticals Releases Q1 2022 Financial Results, Business Update
November 29, 2021
InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021
November 29, 2021
Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE:
Via
Benzinga
InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs
November 29, 2021
Via
Investor Brand Network
InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2022 Financial Results, Business Update Showing Positive Momentum Across All Its Programs
November 29, 2021
Via
CannabisNewsWire
InMed Pharmaceuticals Announces Participation in Upcoming Cannabis Conference
November 23, 2021
InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing, and commercialization of rare cannabinoids, will be participating in the 4th annual Cowen Cannabis...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation in Upcoming Cannabis Conference
November 23, 2021
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
Welcome to the Party $INM! Competition or Compliment to $SNDL? — Cannabis Daily November 18, 2021
November 18, 2021
The Best Daily Overview Of The Cannabis Space South Dakota lawmakers recommend bill to legalize marijuana. New York ban...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
44 Stocks Moving In Thursday's Mid-Day Session
November 18, 2021
Gainers Longeveron Inc. (NASDAQ: LGVN) jumped 157% to $7.51. Longeveron said the FDA granted rare pediatric disease designation for the company’s Lomecel-B for the...
Via
Benzinga
Exposures
Product Safety
54 Biggest Movers From Yesterday
November 19, 2021
Gainers Longeveron Inc. (NASDAQ: LGVN) shares climbed 135.3% to close at $6.87 on Thursday. Longeveron said the FDA granted rare pediatric disease designation for the company...
Via
Benzinga
Exposures
Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
November 18, 2021
Good morning, investor! We're getting right into the thick of it today with a look at the biggest pre-market stock movers for Thursday!
Via
InvestorPlace
24 Stocks Moving in Thursday's Pre-Market Session
November 18, 2021
Gainers Sono Group N.V. (NASDAQ: SEV) rose 33% to $50.80 in pre-market trading. Sono Group shares climbed 155% on Wednesday after the company priced its IPO at $15 per share....
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
InMed Pharmaceuticals Working to Address Rare Cannabinoid Opportunities
November 17, 2021
InMed Pharmaceuticals (NASDAQ:
Via
Benzinga
InMed Pharmaceuticals (INM): Progress Across the Business
November 17, 2021
LONDON, UK / ACCESSWIRE / November 17, 2021 / With the recent closing of the BayMedica acquisition, InMed now has a substantially different profile than just a few months ago. The company is now in its...
From
Edison Investment Research Limited
Via
AccessWire
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Working on Answer to Mass Production of Rare, Otherwise Depleted Cannabinoid Opportunities
November 16, 2021
Via
Investor Brand Network
Topics
Cannabis
Exposures
Cannabis
InMed Pharmaceuticals Files Patent Application for Treatment of Neurodegenerative Diseases with Rare Cannabinoid
November 11, 2021
InMed Pharmaceuticals has filed an international patent application that specifies a rare cannabi...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
InMed Pharmaceuticals Inc. (NASDAQ: INM) Files International Patent Application for Treating Neurodegenerative Diseases Using a New Rare Cannabinoid
November 10, 2021
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
InMed Pharmaceuticals Inc. (NASDAQ: INM) Files International Patent Application for Treating Neurodegenerative Diseases Using a New Rare Cannabinoid
November 10, 2021
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Financial Results, Business Updates for Q1 2022
November 10, 2021
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
InMed Pharmaceuticals Inc. Files PCT Application for Treating Neurodegenerative Disease Using Rare Cannabinoid
November 03, 2021
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development, and commercialization of rare cannabinoids, today announced its filing of an international patent...
Via
Benzinga
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Files PCT Application for Treating Neurodegenerative Disease Using Rare Cannabinoid
November 03, 2021
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Successful Ginkgo Bioworks SPAC IPO Highlights Available Industry Opportunities
November 02, 2021
Special purpose acquisition company Soaring Eagle Acquisition Corp. combined with Ginkgo Bioworks to form publicly-listed Ginkgo Bioworks Holdings Inc., in what is the largest-...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Successful Ginkgo Bioworks SPAC IPO Highlights Available Industry Opportunities for InMed Pharmaceuticals Inc. (NASDAQ: INM) and Synthetic Cannabinoid Production
November 01, 2021
Via
Investor Brand Network
Topics
Initial Public Offering
Exposures
Securities Market
Successful Ginkgo Bioworks SPAC IPO Highlights Available Industry Opportunities for InMed Pharmaceuticals Inc. (NASDAQ: INM) and Synthetic Cannabinoid Production
November 01, 2021
Via
CannabisNewsWire
Topics
Initial Public Offering
Exposures
Securities Market
55 Biggest Movers From Friday
October 25, 2021
Gainers Phunware, Inc. (NASDAQ: PHUN) shares jumped 471.2% to close at $8.74 on Friday. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World...
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.